SK Bio-Pharmaceuticals Announces FDA's Authorization of IND for SKL15508  
4/17/2013 11:28:58 AM

SEOUL, Korea--(BUSINESS WIRE)--The Korea-based international pharmaceutical company, SK Biopharmaceuticals, announced today the U.S. Food and Drug Administration (FDA) has authorized the Investigational New Drug (IND) application for SKL15508 to treat cognitive impairment associated with schizophrenia (CIAS). SK Biopharmaceuticals has developed this novel drug since 2007, taking the approach that while the existing drugs treat schizophrenia by reducing positive and, in some cases, negative symptoms of the disease, they have little effect on the cognitive impairment that so frequently disrupts the lives of its sufferers.